Blood Sugar News and Research

RSS

Blood sugar concentration, or glucose level, refers to the amount of glucose present in the blood of a human or animal. Normally, in mammals the blood glucose level is maintained at a reference range between about 3.6 and 5.8 mM (mmol/l). It is tightly regulated as a part of metabolic homeostasis.

Lantus and Apidra improve outcomes, decrease glycemic variability: Study

Sanofi-aventis announced today results of a study which demonstrated that patients using Lantus® (insulin glargine [rDNA origin] injection) once-daily and Apidra® (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin. Two abstracts from this study were highlighted at the American Diabetes Association's 70th Annual Scientific Sessions (ADA).

29 Jun 2010

Phytonutrient-based medical food and heart-healthy diet reduce CVD risk factors: Study

New research presented at the American Diabetes Association's 70th Scientific Sessions in Orlando, Florida on June 27, 2010 suggests that a medical food developed by Metagenics, Inc. called UltraMeal® PLUS 360° enhances the cardiovascular disease (CVD) risk-lowering benefits of a Mediterranean-style low-glycemic-load diet.

29 Jun 2010

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients who were treated with insulin (with or without oral anti-diabetes medications (OADs)), compared to placebo plus insulin (with or without OADs).

29 Jun 2010

School-based program lowers obesity and risk factors for type 2 diabetes in high risk youth

An intervention in middle schools lowered the obesity rate in students at highest risk for type 2 diabetes, those who started out overweight or obese in sixth grade, an NIH-funded study has found. However, schools that implemented the program did not differ from comparison schools in the study's primary outcome-the prevalence of overweight and obesity combined-which had declined 4 percent in both groups of schools by the end of the three-year study.

29 Jun 2010

Artificial pancreas holds promise for treating Type 1 diabetes

Shawna Wood would like nothing better than to go back to bed for another 24 hours of perfect blood sugar control. The 50-year old Wilsonville, Ore. woman has Type 1 diabetes, and she recently took part in a clinical trial of an automated replacement for her pancreas, which stopped producing insulin 9 years ago.

29 Jun 2010

AFREZZA provides long-term glucose control in Type 2 diabetics: Study

AFREZZA (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, investigational ultra rapid acting mealtime insulin, as part of a diabetes treatment regimen, provides long-term glucose control comparable to usual insulin therapy but with a significantly reduced incidence of hypoglycemia and less weight gain in patients with Type 2 diabetes, according to a two-year study presented today at the American Diabetes Association's 70th Scientific Sessions.

29 Jun 2010

High-phenolic-content olive oil modifies genes that promote inflammation

Health conscious consumers have long known that virgin olive oil is a good choice when it comes to preparing meals and dipping breads. Now, a team of researchers, including one with the Agricultural Research Service (ARS), has found that phenolic components in olive oil actually modify genes that are involved in the inflammatory response.

29 Jun 2010

Pittsburgh companies using wellness to try to keep health costs down

Pittsburgh companies are using wellness incentives in the workplace to trim their health care costs as "small businesses prepare for a lift in their efforts to keep workers healthy, courtesy of health care reform," the Pittsburgh Business Times reports.

28 Jun 2010

Clinical study results show no increased risk of CV events associated with SYMLIN injection

Amylin Pharmaceuticals, Inc. today announced results from an analysis of an integrated database of clinical studies that showed no increased risk of cardiovascular events associated with SYMLIN (pramlintide acetate) injection use compared to a pooled comparator group treated with either placebo or rapid-acting insulin. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association in Orlando, Fla.

28 Jun 2010

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTA (exenatide) injection added to Lantus (insulin glargine), which showed patients with type 2 diabetes achieved glucose targets without weight gain or increasing their risk of hypoglycemia. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association in Orlando, Fla.

28 Jun 2010

UCSB, Sansum achieve milestone in JDRF funded Artificial Pancreas Project

The University of California Santa Barbara (UCSB) and Sansum Diabetes Research Institute (Sansum) announced today the achievement of a milestone in the Artificial Pancreas Project funded by the Juvenile Diabetes Research Foundation (JDRF).

28 Jun 2010

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

Ipsen a global biopharmaceutical group, today announced that its partner Roche disclosed results of five Phase III 24-week studies for taspoglutide for type 2 diabetes at the American Diabetes Association's (ADA) 70th Annual Scientific Sessions. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.

28 Jun 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.

28 Jun 2010

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.

28 Jun 2010

Researchers discover genetic links to kidney failure, diabetic kidney disease

Researchers at the Translational Genomics Research Institute will make two presentations at this week's 70th Scientific Sessions of the American Diabetes Association, June 25-29, in Orlando, Florida.

28 Jun 2010

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Late-breaking Novo Nordisk extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose than Januvia plus metformin at 52 weeks.

28 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Patient health and safety initiatives to be highlighted at ADA annual conference

Roche Diabetes Care, makers of the ACCU-CHEK portfolio of diabetes management products and services, will highlight leading patient health and safety initiatives during the 70th annual American Diabetes Association Annual Conference June 26-28 in Orlando, FL.

From Roche Sequencing and Life Science 24 Jun 2010

High blood sugar in mother during pregnancy leads to reduced insulin sensitivity in children

Children of mothers whose blood glucose (sugar) was high during pregnancy are more likely to have low insulin sensitivity—a risk factor for type 2 diabetes—even after taking into consideration the children's body weight, a new study shows. The results will be presented Tuesday at The Endocrine Society's 92nd Annual Meeting in San Diego.

23 Jun 2010

Blood Sugar News and Research

Further Reading

Lantus and Apidra improve outcomes, decrease glycemic variability: Study

Phytonutrient-based medical food and heart-healthy diet reduce CVD risk factors: Study

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

School-based program lowers obesity and risk factors for type 2 diabetes in high risk youth

Artificial pancreas holds promise for treating Type 1 diabetes

AFREZZA provides long-term glucose control in Type 2 diabetics: Study

High-phenolic-content olive oil modifies genes that promote inflammation

Pittsburgh companies using wellness to try to keep health costs down

Clinical study results show no increased risk of CV events associated with SYMLIN injection

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

UCSB, Sansum achieve milestone in JDRF funded Artificial Pancreas Project

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Researchers discover genetic links to kidney failure, diabetic kidney disease

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Patient health and safety initiatives to be highlighted at ADA annual conference

High blood sugar in mother during pregnancy leads to reduced insulin sensitivity in children

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News